These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 33476895

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A, Drozd B, Glitza IC, Lu H, Patel AB.
    Dermatol Online J; 2020 Aug 15; 26(8):. PubMed ID: 32941716
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
    Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D.
    J Immunother Cancer; 2019 Apr 03; 7(1):96. PubMed ID: 30944020
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
    Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y.
    Lancet Oncol; 2019 Nov 03; 20(11):1506-1517. PubMed ID: 31582355
    [Abstract] [Full Text] [Related]

  • 12. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
    Reich M, Coutzac C.
    Bull Cancer; 2021 Mar 03; 108(3):228-229. PubMed ID: 33531154
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
    Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H.
    Eur J Cancer; 2021 Mar 03; 145():179-182. PubMed ID: 33486441
    [No Abstract] [Full Text] [Related]

  • 15. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.
    Sukari A, Nagasaka M, Abdallah N.
    Oral Oncol; 2018 May 03; 80():100-102. PubMed ID: 29605290
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P, Kotsantis I, Papaxoinis G, Gavrielatou N, Anastasiou M, Pantazopoulos A, Kavourakis G, Gkolfinopoulos S, Panayiotides I, Delides A, Psyrri A.
    Oral Oncol; 2020 Dec 03; 111():105013. PubMed ID: 32977184
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nivolumab in squamous cell carcinoma of the head and neck.
    Specenier P.
    Expert Rev Anticancer Ther; 2018 May 03; 18(5):409-420. PubMed ID: 29560755
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.